Background/Aims: Renal tubular epithelial cells and fibroblasts are the main sources of myofibroblasts, and these cells produce the extracellular matrix during tubulointerstitial fibrosis (TIF). Histone deacetylases (HDAC) inhibitors exert an antifibrogenic effect in the skin, liver and lung. Sirtuin 2 (SIRT2), which is a class III HDAC, is an important member of NAD + -dependent protein deacetylases. The current study evaluated the role of SIRT2 in renal TIF. Methods: Immunohistochemical staining and Western blot were performed to evaluate SIRT2 expression in TIF patients and unilateral urethral obstruction (UUO) mice. Western blot was used to assess the protein levels of SIRT2, α-SMA, collagen III, fibronectin, and MDM2 in tubular epithelial cells and fibroblasts. The specific inhibitor AGK2 was used to inhibit SIRT2 activity, and targeted siRNA was used to suppress SIRT2 expression. Results: SIRT2 expression increased in the tubulointerstitium of TIF patients and UUO mice. SIRT2 inhibition ameliorated TIF in UUO mice. SIRT2 expression in tubular cells was unchanged after exposure to TGF-β1. The SIRT2-specific inhibitor AGK2 did not attenuate TGF-β1-induced tubular epithelialmesenchymal transition. However, SIRT2 was upregulated in fibroblasts, and fibroblasts were activated after TGF-β1 treatment. Genetic knockdown and chemical inhibition of SIRT2 attenuated TGF-β1-induced fibroblast activation. We also explored the downstream signaling of SIRT2 during fibroblast activation. Genetic knockdown and chemical inhibition of SIRT2 suppressed TGF-β1-induced increase in MDM2 expression, and inhibition of the MDM2-p53 interaction using Nutlin-3 did not suppress SIRT2 upregulation. Conclusion: Our results suggest that SIRT2 participates in the activation of fibroblasts and TIF, which is mediated via regulation of the MDM2 pathway, and the downregulation of SIRT2 may be a therapeutic strategy for renal fibrosis.
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Introduction
The incidence and prevalence of chronic kidney disease (CKD) increased greatly in recent years and reached 8-16% worldwide [1] . Many CKD patients progress to end stage renal disease (ESRD), which requires renal replacement therapies. Diabetes, hypertension, and primary glomerulonephritis are the most common causes of CKD. However, the final common pathology of CKD is renal fibrosis, which manifests as glomerulosclerosis and tubulointerstitial fibrosis (TIF) [2] . Renal TIF is characterized by an excessive deposition of extracellular matrix (ECM), inflammatory cell infiltration and myofibroblasts accumulation [3] . Extensive research focused on renal TIF, but the molecular mechanisms still need to be further investigated.
Sirtuin 2 (SIRT2) is a class III histone deacetylase (HDACs) that is associated with metabolic homeostasis [4] , neurodegenerative diseases [5] , tumorigenesis [6] , and inflammatory responses [7] . The early stage of TIF is related to inflammatory responses mediated by infiltrating inflammatory cells, including lymphocytes, macrophages, dendritic cells and mast cells [8] . The inflammatory cells secrete many proinflammatory and profibrotic cytokines, including transforming growth factor-β1 (TGF-β1), which is involved in excessive ECM accumulation and TIF progression [9] . A previous study suggested that SIRT2 promoted hepatic fibrosis, and SIRT2 inhibition attenuated the development of hepatic fibrogenesis [10] . Another study demonstrated that non-specific blockade of the SIRT1/2 pathway attenuated renal fibrosis [11] . Tubular epithelial-mesenchymal transition (EMT) and fibroblast activation are the main mechanisms for TIF progression in kidney. However, the role of SIRT2 in tubular EMT and fibroblast activation still needs to be further clarified.
A previous study reported that the NAD + -dependent protein deacetylase SIRT2 directly deacetylated tumor suppressor p53 in the cytoplasm [12] . Deacetylated p53 inactivates its transcriptional activity, which plays an important role in cellular senescence [13] . An E3-ubiquitin ligase murine double-minute 2 (MDM2) also regulates the tumor suppressor p53. MDM2 overexpression promotes ubiquitylation and proteasomal degradation of p53, which plays a crucial role in tumor progression [14] . Conversely, inhibition of MDM2 re-sensitized rapamycin-resistant renal cancer cells RCC4 and A549 via p53 activation [15] . Another study revealed that MDM2 promoted p53 deacetylation via recruitment of the HDAC1 complex [16] . In kidney, MDM2 is associated with tubular epithelial cell death [17] , podocyte mitotic catastrophe [18] , kidney development [19] and renal cell carcinoma [20] . Our previous study demonstrated that MDM2 participated in fibroblast activation and TIF via a p53-independent pathway [21] . However, the relationship between SIRT2 and MDM2 in renal TIF is unclear.
The present study investigated the role of SIRT2 in renal TIF. We evaluated SIRT2 expression in human renal TIF tissues and unilateral ureteral obstruction (UUO) mice and investigated the effects of SIRT2 in TGF-β1-induced tubular EMT and fibroblast activation. We also examined the downstream molecular mechanism of SIRT2 in TGF-β1-induced fibroblast activation.
Materials and Methods

Human renal biopsy samples
The Department of Nephrology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology collected TIF kidney tissue samples from patients with CKD. Control samples were obtained from para-carcinoma renal tissues without any other kidney diseases. All kidney tissues were fixed in 10% formalin and embedded in paraffin for later use. All patients signed written informed consents. The Ethics Committee of Tongji Medical College, Huazhong University of Science and Technology approved the use of human renal biopsy samples. 
Animal experiments
Immunohistochemical and Masson trichrome staining
Immunohistochemical staining was performed on paraffin-embedded kidney tissues. Kidney tissues were deparaffinized, rehydrated, and incubated with an anti-SIRT2 antibody (1:50, Santa Cruz Biotechnology, Santa Cruz, CA, USA) overnight according to a standard protocol. The tubulointerstitial areas were randomly chosen for imaging. The density of positive areas was measured using Image-Pro Plus 6.0 software (Media Cybernetics, Rockville, MD, USA). Masson trichrome staining was performed on paraffin-embedded kidney tissues using standard procedures. The blue color indicated collagen tissue areas, which were quantitatively calculated using ImageJ software (NIH, Bethesda, MD, USA).
Cell culture and treatment
Rat renal tubular epithelial cells (NRK-52E) were purchased from Western Technology Inc. (Chongqing, China). Rat renal interstitial fibroblasts (NRK-49F) were purchased from American Type Culture Collection (ATCC). Both cell types were cultured in Dulbecco's modified Eagle's medium with F12 (DMEM/F12) containing 10% fetal bovine serum (FBS) and 100 U/ml penicillin-streptomycin. Cells were cultured at 37°C in a 5% CO 2 humidified incubator. TGF-β1 (5 ng/ml, Proteintech Group, Inc., Wuhan, China) was added to NRK-52E and NRK-49F cells and incubated for the indicated times. Cells were pretreated with AGK2 (10 μM) or Nutlin-3 (10 μM, Huaxiang Biotechnology Co., LTD., Shanghai, China) for 1 h prior to TGF-β1 treatment.
SIRT2 siRNA transfection
Cells were grown to 80% confluency and transfected with scrambled siRNA and SIRT2 targeted siRNA (RiboBio Co., Ltd., Guangzhou, China) using lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) for 24 h according to the manufacturer's instructions. TGF-β1 (5 ng/ml) was added after 24 h transfection. The efficiency of transfection was evaluated by Western blot.
Western blot analysis
Kidney tissues and cells were harvested using RIPA buffer (Beyotime Biotechnology, Shanghai, China). The concentrations of harvested proteins were detected using a BCA Protein Assay Kit (Beyotime Biotechnology, Shanghai, China). The same quantity of protein (50 μg) was loaded onto a sodium dodecyl sulfate (SDS)-polyacrylamide gel for electrophoresis. Proteins were transferred to polyvinylidene difluoride (PVDF, Merck Millipore, Darmstadt, Germany) membranes. Membranes were incubated with 5% fat-free milk for 1 h at room temperature and incubated with primary antibodies at 4°C overnight. The following primary antibodies were used: SIRT2 (1:400, Santa Cruz Biotechnology, Santa Cruz, CA, USA), α-smooth muscle actin (α-SMA, 1:1000, Proteintech Group, Inc., Wuhan, China), collagen III (1:500, Proteintech Group, Inc., Wuhan, China), fibronectin (1:1000, Proteintech Group, Inc., Wuhan, China), MDM2 (1:200, Santa Cruz Biotechnology, Santa Cruz, CA, USA), β-actin (1:10000, Santa Cruz Biotechnology, Santa Cruz, CA, USA), and GAPDH (1:1000, Abbikine, CA, USA). All membranes were incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies (1:5000, Abbikine, CA, USA) for 1 h at room temperature. Combined antibodies were visualized using an enhanced chemiluminescence detection kit (Merck Millipore, Darmstadt, Germany) and developed on film. All bands were quantified using ImageJ software.
Statistical analysis
All data are presented as the means ± SEM. Statistical differences between groups were assessed by one-way analysis of variance (ANOVA). P<0.05 was considered as statistically significant.
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Results
SIRT2 is elevated in the tubulointerstitium of TIF patients and UUO mice
To evaluate SIRT2 expression in TIF tissues, immunohistochemical staining was performed to detect SIRT2 expression in renal tubulointerstitium of TIF patients and normal control subjects. SIRT2 expression in renal tubulointerstitium was obviously elevated in patients with TIF compared to normal control subjects, especially in the interstitial areas (Fig.  1A-B) . SIRT2 expression was markedly elevated in UUO mice compared to sham-operated mice on Western blot analyses (Fig. 1C-D) .
Inhibition of SIRT2 activity attenuates TIF in UUO mice
We administered the specific SIRT2 inhibitor AGK2 to UUO mice to investigate the role of SIRT2 in TIF.
Masson trichrome staining revealed tubular dilation, interstitial broadening and increased collagen fibers in UUO mice, and AGK2 administration attenuated collagen deposition in UUO mice ( Fig. 2A) . Masson trichrome-positive areas were semi-quantitatively analyzed. The results revealed an increase in ECM component collagen in UUO mice compared to shamoperated mice. AGK2 administration decreased collagen in UUO mice compared to UUO mice (Fig. 2B) .
TGF-β1 does not influence SIRT2 expression, and AGK2 does not attenuate TGF-β1-induced EMT and ECM accumulation in cultured tubular epithelial cells
Tubular epithelial cells play critical roles in TIF. To explore the role of SIRT2 in vitro, we treated tubular epithelial cells (NRK-52E) with TGF-β1 for 12, 24, and 48 h, and found that SIRT2 protein levels exhibited no significant changes after TGF-β1 stimulation compared with the control group using Western blot analysis (Fig.  3A-B) . Tubular epithelial cells generally undergo EMT and transform to myofibroblasts that express α-SMA and produce excessive ECM after injury [22] . As shown in Fig. 3C -D, TGF-β1 increased the expressions of the myofibroblast marker α-SMA and ECM components collagen III and fibronectin. However, inhibition of SIRT2 activity by AGK2 did not alleviate TGF-β1-induced upregulation of α-SMA, collagen III, or fibronectin. These results indicate that SIRT2 is dispensable in TGF-β1-induced EMT in tubular epithelial cells.
TGF-β1 activates cultured fibroblasts and increases SIRT2 expression in fibroblasts
We clarified the role of SIRT2 in interstitial fibroblast activation. Activated fibroblasts express α-SMA and produce excessive ECM components collagen III and fibronectin. Therefore, the expression of α-SMA, collagen III and fibronectin was observed in fibroblasts 
(NRK-49F) incubated with TGF-β1 for 12, 24, and 48 h. The expressions of these three proteins increased significantly after TGF-β1 exposure (Fig. 4A-B) . TGF-β1 stimulation also elevated SIRT2 protein levels. SIRT2 expression was significantly higher at 12 h and 24 h and peaked at 24 h after TGF-β1 stimulation (Fig. 4C-D) .
Knockdown of SIRT2 by siRNA transfection attenuates TGF-β1-induced fibroblast activation
To investigate the role of SIRT2 in fibroblast activation, NRK-49F cells were transfected with SIRT2 siRNA or scrambled siRNA for 24 h then incubated with TGF-β1 for 24 h. As shown in Fig. 5A -B, targeting siRNA significantly suppressed SIRT2 protein expression. The protein levels of SIRT2, α-SMA, collagen III and fibronectin were significantly lower in SIRT2 siRNA-transfected fibroblasts compared to scrambled siRNA-transfected fibroblasts and untransfected control cells after TGF-β1 exposure (Fig. 5C-D) .
Inhibition of SIRT2 activity attenuates TGF-β1-induced fibroblast activation
To further examine the role of SIRT2 in fibroblast activation, NRK-49F cells were pretreated with AGK2 for 1 h and incubated with TGF-β1. The expressions of α-SMA, collagen III and fibronectin increased significantly in TGF-β1-stimulated fibroblasts compared to the control group. AGK2-pretreated fibroblasts exhibited lower expressions of these three proteins compared to fibroblasts stimulated with TGF-β1 only (Fig. 6A-B) . These results are consistent with the effects of SIRT2 knockdown on fibroblasts and further confirmed the role of SIRT2 in fibroblast activation. 
SIRT2 inhibition alleviates TGF-β1-induced increase in MDM2 expression
Previous studies revealed that SIRT2 and MDM2 were involved in the tumor suppressor p53 deacetylation [12, 16] . To investigate the mechanism of SIRT2-mediated fibroblast activation, we detected MDM2 expression after TGF-β1 stimulation. As shown in Fig. 7A , TGF-β1 stimulation markedly upregulated MDM2. Knockdown of SIRT2 expression using targeted siRNA transfection reduced MDM2 expression compared to the scrambled siRNA (Fig. 7A-B) . Inhibition of SIRT2 activity by AGK2 also attenuated TGF-β1-induced MDM2 upregulation (Fig. 7C-D) . We used the MDM2 and p53 binding inhibitor Nutlin-3 and detected SIRT2 expression by Western blot. Nutlin-3 did not reduce TGF-β1-induced SIRT2 upregulation (Fig. 7E-F) .
Discussion
Mammalian SIRTs are a family of NAD + -dependent HDACs that are implicated in a variety of diseases, such as metabolic, age-related, neurodegenerative, cancer and proliferative diseases [23] . There are seven SIRTs, SIRT1-SIRT7, in mammals. SIRT1 is primarily located in the nucleus, and SIRT2 is a cytoplasmic protein. SIRT3, SIRT4 and SIRT5 are primarily located in the mitochondria, and SIRT6 and SIRT7 are predominantly located in the nucleus [24] . This diverse subcellular localization determines their distinct functions. SIRT2 colocalizes with microtubules and deacetylates α-tubulin [25] , histone H4 substrates and forkhead transcription factor class O [26, 27] . SIRT2 also interacts with NF-κB family member p65 [28] . Therefore, SIRT2 is involved in many cellular processes, including cell cycle, microvascular inflammation [29] , cancer cell proliferation [30] , autophagy and apoptosis [31] . Several small molecule inhibitors of SIRTs were reported recently, such as splitomicin and its derivatives, sirtinol, AGK2, cambinol, suramin and tenovin [24] . Class I and II HDACs inhibitors exert anti-inflammatory and anti-fibrotic effects in kidney diseases [32] . Inhibition of the SIRT2 pathway is also anti-fibrotic. A previous study revealed that SIRT2 promoted hepatic fibrosis and SIRT2 inhibition suppressed hepatic fibrogenesis [10] . Jung et al. [33] found that SIRT2 regulated CXCL2 and CCL2 expression in lipopolysaccharide Another study demonstrated that SIRT2 played a protective role in LPS-induced neuroinflammation [34] . In this study, we found that SIRT2 expression increased significantly in human TIF tissues and the kidney tissues of UUO mice. Inhibition of SIRT2 activity ameliorated renal TIF in UUO mice. These results are consistent with former studies and demonstrate that SIRT2 plays a critical role in inflammation and fibrosis. The development of renal TIF depends on myofibroblasts because these cells produce a large quantity of ECM components, including collagens and fibronectin. Cellular sources of myofibroblasts generally include resident fibroblasts, tubular epithelial cells, microvascular pericytes, fibrocytes, bone marrow-derived myofibroblasts and endothelial cells [35] . In the tubulointersitium, tubular epithelial cells are the initial site of injury, and then interstitial fibroblasts are activated [9] . Tubular epithelial cells undergo EMT under many pathophysiological conditions [36] . This process promotes tubular epithelial cell transformation into profibrotic myofibroblasts that express the myofibroblast marker α-SMA [37, 38] . Resident fibroblasts are activated and become myofibroblasts expressing α-SMA after injury [39, 40] . TGF-β1 is the most important primary driver and mediator during renal interstitial fibrosis. Tubular and interstitial cells synthesize TGF-β1. TGF-β1 mediates tubular EMT and fibroblast activation, which leads to excessive ECM accumulation and TIF [41] . Our study demonstrated that SIRT2 was expressed in tubular epithelial cells. However, TGF-β1 stimulation did not alter SIRT2 expression and the SIRT2 inhibitor AGK2 did not rescue TGF-β1-induced upregulation of α-SMA, collagen III and fibronectin in tubular epithelial cells. These findings differ from another study that demonstrated the involvement of SIRT2 in renal inflammatory injury via regulation of renal tubular CXCL2 and CCL2 expression [33] . These differences may be attributed to the different roles of SIRT2 in renal fibrosis. Then, we used renal interstitial fibroblasts to evaluate the effects of TGF-β1. Our results demonstrated that the levels of α-SMA, collagen III and fibronectin proteins were increased significantly after TGF-β1 treatment in renal interstitial fibroblasts. These results suggest that TGF-β1 induces fibroblast activation. We also found that TGF-β1 upregulated SIRT2, which was most obvious at 24 h. Downregulation of SIRT2 using siRNA or specific inhibition of SIRT2 using AGK2 suppressed TGF-β1-induced fibroblast activation. Therefore, SIRT2 deficiency exerts anti-fibrosis effects via inhibition of fibroblast activation. Taken together, these data suggest that renal interstitial fibroblasts, rather than tubular epithelial cells, are engaged in SIRT2-associated renal TIF.
We further explored the molecular mechanism of SIRT2 in TGF-β1-induced fibroblast activation. Our previous study demonstrated that MDM2 was also associated with fibroblast activation and TIF progression [21] . The ubiquitin E3 ligase MDM2 is an oncogene that negatively regulates tumor suppressor p53, which is upregulated in a variety of cancer cells [42] . MDM2 reactivated p53 via polyubiquitylation and inhibited its transcriptional activity [43] . Another study demonstrated that SIRT2 deacetylated p53 and inhibited its transcriptional activity [44] . However, the relationship between SIRT2 and MDM2 is not clear. The current study investigated MDM2 expression after TGF-β1 stimulation and found that TGF-β1 stimulation upregulated MDM2, and SIRT2 inhibition suppressed TGF-β1-induced MDM2 upregulation. However, disruption of the MDM2-p53 interaction using Nutlin-3 did not inhibit TGF-β1-induced increased SIRT2 expression. These results indicate that SIRT2 is the upstream regulator of MDM2, and it plays important roles in TGF-β1-induced fibroblast activation and renal TIF progression via the MDM2 signaling pathway.
Conclusion
In summary, the present study demonstrated the involvement of SIRT2 in fibroblast activation and renal TIF. SIRT2 inhibition suppressed fibroblast activation via the MDM2 signaling pathway. Therefore, the SIRT2-MDM2 signaling pathway may be a therapeutic target for renal fibrosis.
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